Hawboldt John, Bader Mazen
School of Pharmacy, Health Sciences Centre, Department of Pharmacy, Eastern Health, St. John's, Newfoundland, Canada.
Ann Pharmacother. 2007 Nov;41(11):1906-11. doi: 10.1345/aph.1K308. Epub 2007 Sep 18.
To report a case of aseptic meningitis induced by intramuscularly administered methotrexate in a patient with rheumatoid arthritis.
A 62-year-old male presented on 3 separate occasions with symptoms consistent with aseptic meningitis: 2 required hospitalization and 1 was noted during a subsequent ambulatory care visit. Prior to the first episode, the methotrexate dose ranged between 17.5 mg and 20 mg given once weekly over 5 years, 11 months. One month before the patient's first admission, the dose was increased to 22.5 mg. Symptoms on presentation included headache, neck stiffness, and fever. Cerebrospinal fluid testing indicated pleocytosis and low glucose level. Methotrexate was discontinued but was restarted 2 weeks after hospital discharge at the same dose and resulted in a second hospitalization for aseptic meningitis. Upon discharge from the second hospitalization, methotrexate was withheld. After a 2 month withdrawal period and rechallenge, the symptoms returned within 3 days. The drug was then discontinued.
Methotrexate-induced aseptic meningitis has been reported in the literature; however, in those cases, the effect occurred only when methotrexate was given via the intrathecal route. We identified 7 relevant articles via a search of MEDLINE, International Pharmaceutical Abstracts, and EMBASE (1970-August 3, 2007): 3 were review articles, 2 were case series, and 2 were case reports. All of the series and reports involved patients with leukemia. The available literature suggests that aseptic meningitis is associated with long-term use of methotrexate or recent dose escalation. A definitive mechanism for methotrexate-induced aseptic meningitis is not known. The Naranjo probability scale indicates a probable relationship between the development of the condition and the methotrexate use in our patient.
Aseptic meningitis has been previously associated with intrathecal use of methotrexate. Our report describes the first case of aseptic meningitis that occurred in a patient being treated with intramuscular methotrexate.
报告1例类风湿关节炎患者因肌内注射甲氨蝶呤诱发无菌性脑膜炎的病例。
一名62岁男性3次出现符合无菌性脑膜炎的症状:2次需要住院治疗,1次是在随后的门诊就诊时发现。在首次发作之前,甲氨蝶呤剂量为17.5毫克至20毫克,每周一次,持续5年11个月。在患者首次入院前1个月,剂量增加至22.5毫克。就诊时症状包括头痛、颈部僵硬和发热。脑脊液检查显示细胞增多和葡萄糖水平降低。甲氨蝶呤停药,但出院2周后以相同剂量重新开始使用,导致因无菌性脑膜炎再次住院。第二次住院出院后,停用甲氨蝶呤。经过2个月的停药期并再次激发,症状在3天内再次出现。然后停用该药物。
文献中曾报道过甲氨蝶呤诱发无菌性脑膜炎的病例;然而,在那些病例中,这种效应仅在通过鞘内途径给予甲氨蝶呤时才会出现。我们通过检索MEDLINE、《国际药学文摘》和EMBASE(1970年至2007年8月3日)确定了7篇相关文章:3篇为综述文章,2篇为病例系列,2篇为病例报告。所有系列和报告均涉及白血病患者。现有文献表明,无菌性脑膜炎与甲氨蝶呤的长期使用或近期剂量增加有关。甲氨蝶呤诱发无菌性脑膜炎的确切机制尚不清楚。Naranjo概率量表表明该病症的发生与我们患者使用甲氨蝶呤之间可能存在关联。
无菌性脑膜炎以前曾与鞘内使用甲氨蝶呤有关。我们的报告描述了首例在接受肌内注射甲氨蝶呤治疗的患者中发生无菌性脑膜炎的病例。